Congress Should Not Impose Foreign Price Controls On Innovative Drugs
By: bitcoin ethereum news|2025/05/04 09:00:01
0
Share
VALUE and PRICE balancing Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. If implemented, this policy will make a bad situation much worse. The logic for implementing the MFN is simple – if patients in the U.K. or Canada are paying less money for a drug, then so should patients in the U.S. But the prices for innovative drugs in many OECD countries are only lower because these nations impose strict price controls, which always come with a high cost. To start with, price controls diminish drug availability. Thanks to price controls, patients in the other major industrialized countries (OECD) have access to only 29% of new medicines while patients in the U.S. have access to 85%. Even worse, patients in Canada and the U.K. can wait years for access to the latest treatments in some cases, and at any given time in Canada, there is a shortage of between 1,500 and 2,000 drugs. In those cases where the drugs are available in foreign nations, adopting the MFN policy outsources U.S. health policy to these countries. The U.S. should not impose price controls, but if it does, drug pricing decisions should not be outsourced to the EU, UK, or Canada. Adopting the MFN will also harm innovation. Developing a new drug takes a lot of time and money. On average, developing one innovative drug takes over $2.9 billion (including post-marketing expenditure) and between 10 and 15 years. It is also a risky endeavor. Approximately 9 out of every 10 drugs that reach the clinical trial stage will ultimately fail. Drug price controls make it harder for innovative firms to cover their capital costs, which reduces the amount of money spent on new innovations. A University of Chicago Issue Brief by Philipson and Durie found “that a 1 percent reduction in revenue leads to a 1.5 percent reduction in R&D activity.” The consequences from disincentivizing innovation would hit the U.S. economy hard. According to the latest industry economic impact report, the biotechnology industry directly contributed $1.4 trillion to the economy in 2023 (around 6.8% of the private sector GDP), supported nearly 2.3 million jobs, and paid hundreds of billions of dollars in taxes to the federal government. Perhaps even more important, the lost innovation from price controls harms patients currently living with diseases that have inadequate or no treatment options. If price controls are adopted in the U.S., then patients living with Alzheimer’s disease, pancreatic cancer, or muscular dystrophy may end up waiting in vain for efficacious treatments. Ultimately, the problem is that foreign governments are imposing price controls on drugs. The result is that patients across the globe benefit from American pharmaceutical innovation without paying their fair share of the innovation’s costs. The best way to address this problem is to defend the intellectual property of U.S. firms in trade negotiations. Executing on this goal could include appointing a pharmaceutical trade negotiator at USTR to defend American companies’ interests. Successfully concluding these negotiations is a long-term project, however. There are beneficial reforms that Congress can implement now that will promote greater drug availability in the meantime. These reforms should address the many inefficiencies that plague the U.S. drug market. For instance, more than half of the revenues from drug sales goes to hospitals, pharmacies, and other middlemen thanks to errant policies. These errant policies include the 340B drug discount program, which now has the contradictory impact of raising overall drug prices. Reforms should demand greater transparency in the program and mandate 340B only serves its intended population. These changes will improve 340B’s effectiveness while relieving the inflationary price pressures created by the program. Another necessary reform would address the current opaque drug pricing system that is empowering pharmacy benefit managers (PBMs) to the detriment of patients. Thanks to the system’s misaligned incentives, costs are being inequitably shifted to patients. Worsening the problem, the system often encourages the use of more expensive medicines rather than lower cost alternatives. Reining in PBMs will improve the drug market’s incentives resulting in lower out-of-pocket costs for patients without diminishing the incentives for innovation. The FDA approval process is also slow and overly burdensome. Reforming this process can lower the cost of developing new treatments while expediting their availability to patients. The goal of U.S. drug policy should be to promote the dual goals of innovation and broad-based affordability. The MFN policy adopts foreign imposed price controls that will discourage innovation and reduce patients access to medicines. While spending on medicine may go down, total healthcare spending is likely to increase as patients wind up requiring more expensive surgeries and hospital stays. Promoting more affordable drugs is not simple. It requires the hard work of understanding what is driving the problem and implementing policies that directly fix them. The MFN is a shortcut that patients will quickly come to regret. Source: https://www.forbes.com/sites/waynewinegarden/2025/05/03/congress-should-not-impose-foreign-price-controls-on-innovative-drugs/
You may also like

The large models in the United States are moving towards closure in the name of security
The government successfully inserted itself as an approver between commercial AI models and their users for the first time.

Morning Report | CoinEx becomes a key hub for Iran to evade sanctions, involving over $3.8 billion in funds; Kalshi seeks a new round of financing, with a valuation potentially rising to $40 billion
Overview of Important Market Events on June 25

From the white-haired stock god to the billionaire fund mogul, the smart people shorting Nvidia are all getting rich using the same framework
Give up on heavily investing in Nvidia's "nine major bottlenecks"! This article analyzes the underlying logic behind top AI investors making billions: physical infrastructure such as electricity, HBM, and optical interconnects are the true keys to wealth in AI hardware.

Why do cryptocurrency projects always like to change their names?
In many cases, the old names of encryption projects have no competitive advantage, only historical baggage.

Global Launch: As predictions become the most scarce asset in the AI era, Manadia is defining the next generation of the value internet
The trusted AI prediction ecosystem Manadia, which has secured $7 million in funding from well-known institutions like OKX, will globally launch in June. The core token UMXM has already been listed on multiple mainstream platforms, inviting you to seize the new blue ocean of the trillion-level predi...

Who is footing the bill for the $64 billion accounting frenzy?
Affected by Bitcoin falling below $60,000, publicly listed companies heavily invested in this asset are facing huge paper losses and valuation discounts, and their debt structure and accounting standards may trigger structural liquidity risks in the future.

I never expected that the first application of AI x Crypto would be in security auditing
AI has accelerated attack efficiency and also promoted the upgrade of defense systems. The security audit sector is undergoing a transition from a dividend model to a competitive model.

What is your view on Binance's competitive advantages?
When the dividends of rule arbitrage gradually approach zero, can we produce product strength, governance capability, and trust that are commensurate with its scale?

ETH has entered a non-consensus phase, and the turning point is approaching!
This has nothing to do with the Ethereum Foundation or Ethlabs; Ethereum needs to win by solving real problems.

The shift in the cloud of the air: from despising stablecoins a year ago to the high-profile entry of capital today
It can continue to question the cost-effectiveness of stablecoins in the G10 currency corridor, but it cannot ignore the structural opportunities of stablecoins in emerging markets, corporate finance, and on-chain settlements.

The survival dilemma of small and medium exchanges behind the withdrawal anomalies exposed by AscendEX
The living space is constantly being compressed.

Why Is Bitcoin Falling Below $60K? 5 Key Market Drivers Explained
Bitcoin has dropped sharply amid ETF outflows, Strategy stock weakness, AI stock rallies, and changing Fed expectations. Explore the key forces driving BTC’s latest correction and what traders should watch next.

Bitcoin vs. Gold in 2026: Which Asset Performs Better in Different Markets?
Bitcoin vs. gold in 2026: Why are both assets falling, and what does their changing correlation mean? Discover what drives Bitcoin and gold prices and how traders can navigate different market conditions.

Morning News | The draft amendment to the People's Bank of China Law aims to clarify the legal status of digital renminbi; South Korea will transfer about 40 unregistered virtual asset service providers to law enforcement agencies
Overview of Important Market Events on June 24

The cryptocurrency industry has entered the "Show Me" era: merely relying on vision is no longer enough
The awareness level of the audience in the cryptocurrency industry—including media, institutions, and retail investors—is steadily increasing, and this trend has become a foregone conclusion.

Interpreting the Ethereum Foundation's new structure: Reaffirming self-sovereignty amid institutional trends
The Ethereum Foundation has announced a new five-layer working framework, clarifying the focus of future development and reaffirming its commitment to decentralized core values amidst the wave of institutionalization.

Former SpaceX engineer reconstructs the financial execution system using first principles
Plan Execution Lab completes angel round financing for Singapore family office, with a valuation of 50 million USD.

Standard Chartered Bank sings a 50x rhapsody again, aiming for AAVE to reach 3500 USD
The throne of DeFi lending still exists, but the foundation beneath the throne needs to undergo a reconstruction or reinforcement.
The large models in the United States are moving towards closure in the name of security
The government successfully inserted itself as an approver between commercial AI models and their users for the first time.
Morning Report | CoinEx becomes a key hub for Iran to evade sanctions, involving over $3.8 billion in funds; Kalshi seeks a new round of financing, with a valuation potentially rising to $40 billion
Overview of Important Market Events on June 25
From the white-haired stock god to the billionaire fund mogul, the smart people shorting Nvidia are all getting rich using the same framework
Give up on heavily investing in Nvidia's "nine major bottlenecks"! This article analyzes the underlying logic behind top AI investors making billions: physical infrastructure such as electricity, HBM, and optical interconnects are the true keys to wealth in AI hardware.
Why do cryptocurrency projects always like to change their names?
In many cases, the old names of encryption projects have no competitive advantage, only historical baggage.
Global Launch: As predictions become the most scarce asset in the AI era, Manadia is defining the next generation of the value internet
The trusted AI prediction ecosystem Manadia, which has secured $7 million in funding from well-known institutions like OKX, will globally launch in June. The core token UMXM has already been listed on multiple mainstream platforms, inviting you to seize the new blue ocean of the trillion-level predi...
Who is footing the bill for the $64 billion accounting frenzy?
Affected by Bitcoin falling below $60,000, publicly listed companies heavily invested in this asset are facing huge paper losses and valuation discounts, and their debt structure and accounting standards may trigger structural liquidity risks in the future.
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Program:support@weex.com
